| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $37,344,096 | 21 | 100 |
| Lu Hongbo | director | 0 | $0 | 1 | $228,334 | $-228,334 |
| Waddill William D. | director | 0 | $0 | 1 | $566,038 | $-566,038 |
| Vakiener Victoria | director | 0 | $0 | 1 | $679,491 | $-679,491 |
| OLUKOTUN ADEOYE Y | director | 0 | $0 | 2 | $850,543 | $-850,543 |
| Apel Daniel Joseph | Chief Financial Officer | 0 | $0 | 1 | $934,285 | $-934,285 |
| Ferrari Mauro | director | 0 | $0 | 2 | $1.02M | $-1.02M |
| PERRY MICHAEL S | director | 0 | $0 | 2 | $2M | $-2M |
| O'Brien Patrick | COO | 0 | $0 | 1 | $3.12M | $-3.12M |
| Hamilton James C | Chief Medical Officer | 0 | $0 | 3 | $3.93M | $-3.93M |
| Anzalone Christopher Richard | Chief Executive Officer | 0 | $0 | 7 | $24.01M | $-24.01M |
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase …
Over the last 12 months, insiders at Arrowhead Pharmaceuticals, Inc. have bought $0 and sold $37.34M worth of Arrowhead Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Arrowhead Pharmaceuticals, Inc. have bought $63,231 and sold $18.44M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $27,500 was made by Lu Hongbo (director) on 2024‑03‑20.
| 2026-08-18 | Sale | PERRY MICHAEL S | director | 11,600 0.0082% | $87.30 | $1.01M | -25.08% | |
| 2026-08-18 | Sale | OLUKOTUN ADEOYE Y | director | 2,000 0.0014% | $86.96 | $173,920 | -25.08% | |
| 2026-05-12 | Sale | Lu Hongbo | director | 2,970 0.0021% | $76.88 | $228,334 | -2.40% | |
| 2026-04-23 | Sale | Hamilton James C | Chief Medical Officer | 10,000 0.0072% | $75.00 | $750,000 | +2.79% | |
| 2026-04-22 | Sale | Apel Daniel Joseph | Chief Financial Officer | 13,095 0.009% | $71.35 | $934,285 | +3.35% | |
| 2026-03-05 | Sale | Hamilton James C | Chief Medical Officer | 10,000 0.0072% | $64.19 | $641,900 | +16.17% | |
| 2026-01-05 | Sale | O'Brien Patrick | COO | 49,493 0.0354% | $63.11 | $3.12M | +10.63% | |
| 2026-01-05 | Sale | Hamilton James C | Chief Medical Officer | 40,164 0.0287% | $63.11 | $2.53M | +10.63% | |
| 2026-01-02 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 13,187 0.0095% | $66.10 | $871,703 | +4.15% | |
| 2025-12-29 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 51,726 0.0369% | $69.13 | $3.58M | +0.73% | |
| 2025-12-26 | Sale | Ferrari Mauro | director | 7,530 0.0054% | $70.00 | $527,100 | -0.41% | |
| 2025-12-22 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 12,586 0.009% | $68.44 | $861,340 | +1.61% | |
| 2025-12-19 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 13,445 0.0097% | $67.66 | $909,683 | +2.66% | |
| 2025-12-19 | Sale | Waddill William D. | director | 8,367 0.006% | $67.65 | $566,038 | +2.66% | |
| 2025-12-19 | Sale | Vakiener Victoria | director | 10,040 0.0072% | $67.68 | $679,491 | +2.66% | |
| 2025-12-19 | Sale | OLUKOTUN ADEOYE Y | director | 10,000 0.0072% | $67.66 | $676,623 | +2.66% | |
| 2025-12-17 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 85,000 0.0608% | $64.04 | $5.44M | +7.60% | |
| 2025-12-16 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 54,298 0.0359% | $62.58 | $3.4M | +7.67% | |
| 2025-12-15 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 130,000 0.0946% | $68.85 | $8.95M | +1.69% | |
| 2025-12-05 | Sale | PERRY MICHAEL S | director | 16,250 0.0117% | $61.03 | $991,738 | +13.20% |
| Anzalone Christopher Richard | Chief Executive Officer | 3792739 2.685% | $225.78M | 4 | 51 | <0.0001% |
| Ferrari Mauro | director | 69053 0.0489% | $4.11M | 2 | 6 | +71% |
| Lu Hongbo | director | 52012 0.0368% | $3.1M | 3 | 1 | <0.0001% |
| Myszkowski Kenneth Allen | Chief Financial Officer | 455433 0.3224% | $27.11M | 1 | 29 | <0.0001% |
| KNOTT DAVID M | 10 percent owner | 166778 0.1181% | $9.93M | 1 | 3 | <0.0001% |
| GIVEN DOUGLAS B | director | 124167 0.0879% | $7.39M | 1 | 21 | <0.0001% |
| McKenney Charles | director | 17220 0.0122% | $1.03M | 1 | 16 | |
| De Backer Marianne | director | 17000 0.012% | $1.01M | 9 | 2 | +50.28% |
| Kingsley Joseph Theodore III | Interim President & CFO | 12000 0.0085% | $714,360.00 | 2 | 0 | +27.7% |
$159,914,414 | 243 | 18.52% | $8.86B | |
$67,892,722 | 138 | 28.28% | $6.25B | |
$273,531,368 | 93 | 38.24% | $9.16B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$613,304,943 | 46 | 11.85% | $6.22B |
| Increased Positions | 248 | +75.15% | 15M | +13.53% |
| Decreased Positions | 145 | -43.94% | 13M | -11.05% |
| New Positions | 123 | New | 6M | New |
| Sold Out Positions | 29 | Sold Out | 872,791 | Sold Out |
| Total Postitions | 433 | +31.21% | 117M | +2.48% |
| Blackrock, Inc. | $1.37M | 14.87% | 20.22M | +799,938 | +4.12% | 2025-09-30 |
| Vanguard Group Inc | $1.09M | 11.79% | 16.04M | +510,798 | +3.29% | 2025-09-30 |
| Avoro Capital Advisors Llc | $738,911.00 | 8.02% | 10.9M | +300,000 | +2.83% | 2025-09-30 |
| State Street Corp | $433,677.00 | 4.7% | 6.4M | +26,308 | +0.41% | 2025-09-30 |
| Fmr Llc | $390,459.00 | 4.24% | 5.76M | +589,520 | +11.4% | 2025-09-30 |
| Slate Path Capital Lp | $337,730.00 | 3.66% | 4.98M | -250,000 | -4.78% | 2025-09-30 |
| Geode Capital Management, Llc | $212,253.00 | 2.3% | 3.13M | +152,537 | +5.12% | 2025-09-30 |
| Siren, L.L.C. | $180,991.00 | 1.96% | 2.67M | 0 | 0% | 2025-09-30 |
| Driehaus Capital Management Llc | $142,318.00 | 1.54% | 2.1M | +2M | New | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $141,118.00 | 1.53% | 2.08M | +2M | +3,142.51% | 2025-09-30 |